Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Total Liabilities (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Total Liabilities for 5 consecutive years, with $35.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 64.68% year-over-year to $35.0 million, compared with a TTM value of $35.0 million through Dec 2025, down 64.68%, and an annual FY2025 reading of $35.0 million, down 64.68% over the prior year.
  • Total Liabilities was $35.0 million for Q4 2025 at Aligos Therapeutics, down from $37.9 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $99.1 million in Q4 2024 and bottomed at $31.0 million in Q3 2023.
  • Average Total Liabilities over 5 years is $45.9 million, with a median of $41.8 million recorded in 2022.
  • The sharpest move saw Total Liabilities skyrocketed 84.13% in 2024, then crashed 64.68% in 2025.
  • Year by year, Total Liabilities stood at $50.6 million in 2021, then fell by 15.49% to $42.8 million in 2022, then skyrocketed by 38.92% to $59.4 million in 2023, then soared by 66.65% to $99.1 million in 2024, then tumbled by 64.68% to $35.0 million in 2025.
  • Business Quant data shows Total Liabilities for ALGS at $35.0 million in Q4 2025, $37.9 million in Q3 2025, and $32.8 million in Q2 2025.